SKIP TO CONTENT
About Abbott
Contact
International | eng
Country Language

CARDIOVASCULAR

International | eng
Country Language

CLEAR

Streamlining Peripheral Artery Disease (PAD) Referral and Diagnosis to Improve Quality of Life1

CLEAR Peripheral Artery Disease Treatment Referral Program

Introducing Abbott's New CLEAR Program

Developed by Abbott, based on physician and patient insights, to help patients with PAD get a timely diagnosis followed by appropriate treatment

CLEAR delivers tailor made educational resources to all involved in the PAD referral process:

  • Enhance awareness and understanding of PAD
  • Facilitate early referral of patients
  • Boost networking and collaboration between referring HCPs and vascular specialists
  • Provide easy-to-use tools to streamline referral pathway efficiency
  • Help prevent PAD progression to CLTI, save patients' limbs and improve quality of life1
  • Connect with an Abbott Representative to learn more on how you can get started quickly and simply.

Access further information on PAD for yourself and your patients.

Register to receive a toolkit with these materials and more

  • PAD management guidelines that provide the flow of PAD diagnosis and treatment according to current standard-of-care clinical guidelines
  • A brochure to help your patients better understand PAD
  • Patient-facing posters that highlight PAD risk factors and anatomy for your use in exam rooms
  • A PAD risk checklist for your use with patients to assess PAD risk
  • A simple guide for descriptions and instructions on how to use all the materials provided
Request Toolkit
Peripheral Artery Disease (PAD) Toolkit Request

Help your patient understand PAD

Patients diagnosed with peripheral artery disease (PAD) are likely to be concerned about their condition and will want to learn all they can about PAD and how it may affect them. PAD is a common disease affecting over 236 million people worldwide3 and presents in 15-20% of people >70 years of age.4

PAD is the presence of atherosclerotic arteries in the lower limbs, which leads to a reduction in blood flow to the extremities.5,6 PAD is associated with significant morbidity and mortality:

  • 5-year mortality rate of 33%7
  • 1 in 5 risk of MI, stroke, cardiovascular death, or hospitalization within one year8
  • Prevalence that increases 2-fold every 10 years9
  • Significant impact on health-related quality of life2,10

Chronic limb-threatening ischemia (CLTI) is the most severe form of PAD affecting ~2 million people in the U.S.11 and is associated with rest pain, ulceration, and gangrene (>2 weeks) which could lead to significant limb loss, decrease quality of life and mortality.12

Peripheral Artery Disease Patient Education Statistics
image
image

The information provided is not intended for medical diagnosis or treatment or as a substitute for professional medical advice.
Consult with a physician or qualified healthcare provider for appropriate medical advice.
This material is intended for use with healthcare professionals only.
 

Back to top


References:

  1. Walker, C.M., et al. Clin Interv Againg 2015: 10; 1147-1153
  2. Wu A, et al. J Am Heart Assoc. 2017; 6(1): e004519.
  3. Song P, et al. Lancet Glob Health. 2019; 7(8): e1020-30.
  4. Norgren L, et al. J Vasc Surg. 2007; 45(1): S5-67.
  5. Hirsch AT, et al. JAMA. 2001; 286(11): 1317-24.
  6. Peripheral Arterial Disease (PAD). CDC. Web. 27 Sep 2021.
  7. Tomson J, Lip GYH. BMC Cardiovasc Disord. 2005; 5: 15.
  8. Steg G, et al. JAMA. 2007; 297(11): 1197-206.
  9. Virani SS, et al. Circulation. 2021; 143(8): e254-743.
  10. Schorr EN, et al. Geriatr Nurs. 2015; 36(4): 293-300.
  11. Duff S, et al. Vasc Health Risk Manag. 2019; 15; 187-208.
  12. Conte MS, et al. J Vasc Surg. 2019; 70(2): 662

MAT-2308000 v2.0

POLICIES & ADVISORIES
HEALTHCARE PROFESSIONALS
PATIENTS & CAREGIVERS
Abbott logo

Information contained herein for distribution outside the U.S. only.

CAUTION: These products are intended for use by or under the direction of a physician. Prior to use, reference the Instructions for Use, inside the product carton (when available) or online for more detailed information on Indications, Contraindications, Warnings, Precautions and Adverse Events.

Illustrations are artist's representations only and should not be considered as engineering drawings or photographs.

Unless otherwise specified, all product names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company. ™ Indicates a trademark of the Abbott group of companies. ‡ Indicates a third party trademark, which is property of its respective owner.

© 2025 Abbott. All Rights Reserved.

MAT-2001111 v9.0

Disclaimer

You are about to enter an Abbott country- or region-specific website. 

Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions

Do you wish to continue and enter this website? 

YES

MAT-2305078 v1.0